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Our understanding of tuberculosis (TB) is heavily colored 
by the available diagnostic tools. Active TB is identifiable 
first because of the presence of clinical symptoms, such 
as chronic cough, fever and weight loss. Active TB may 
be  confirmed  by  the  identification  of  the  causative 
bacteria, Mycobacterium tuberculosis (Mtb), but in many 
cases bacteria are undetectable. Latent TB is defined by 
the presence of a T-cell-mediated immune response to 
Mtb in an asymptomatic individual. This immunological 
response  to  Mtb  is  widely  believed  to  indicate  the 
presence  of  viable  organisms  that  might  cause  active 
disease in the future, although how many people with a 
detectable  immune  response  actually  harbor  Mtb  is 
unknown. The tests used to identify active and latent Mtb 
infection  are  among  the  oldest  in  modern  medicine, 
dating back to the late 19th century. Thus, much of our 
understanding of human TB has been frozen for more 
than a century.
Can a systematic, molecular approach to understanding 
the host response to Mtb provide new insights into the 
course  of  human  disease?  A  recent  study  by  Anne 
O’Garra and her colleagues suggests that it can [1]. To 
characterize  host  responses  to  Mtb  in  an  unbiased 
manner they chose to use whole-genome transcriptional 
profiling.  They  collected  blood  from  HIV-negative 
patients from the UK with well-demonstrated active TB, 
those with positive tests for latent TB but no evidence of 
active  disease  and  healthy  controls.  The  investigators 
prepared RNA from these blood samples and hybridized 
it to microarrays containing more than 48,000 probes for 
human sequences. Focusing on a training set of samples, 
they used statistical tests and clustering to identify a set 
of 393 genes whose expression is significantly different 
between  patients  with  active  disease  and  those  with 
latent or no disease.
They then looked at the independent test and validation 
groups from the UK and South Africa, respectively, and 
found  that  the  expression  levels  of  these  genes  could 
discriminate  powerfully  between  patients  with  active 
disease and those with no disease [1]. This discrimination 
was  not  perfect,  however.  For  example,  some  patients 
with latent disease clustered with those with active TB. 
Conversely, some with clinically diagnosed disease lacked 
transcriptional  markers.  However,  when  patients  were 
evaluated clinically, those with the most severe disease, at 
least as determined by the extent of abnormality on chest 
X-ray,  had  much  more  pronounced  transcriptional 
changes  than  those  with  minimal  disease.  In  fact,  the 
extent  of  disease  correlated  fairly  well  with  the 
transcriptional  anomalies,  leading  the  authors  [1]  to 
propose that differences in profiles define a ‘molecular 
distance  to  health’.  This  metric  improved  when  the 
disease was treated.
Of course, there are two sides to diagnostic criteria; a 
test might sensitively detect disease but might suffer from 
lack of specificity. Measuring a patient’s temperature, for 
example,  sensitively  detects  infection  but  does  not 
discriminate  among  different  causes.  To  test  for 
specificity, the authors [1] compared the transcriptional 
profiles  in  TB  patients  with  those  seen  in  patients 
infected  with  group  A  Streptococcus  or  Staphylococcus 
aureus,  which  are  Gram  positive  pathogens  like  Mtb, 
although they cause very different clinical syndromes, or 
afflicted  with  the  autoimmune  diseases  systemic  lupus 
erythematosus (SLE) or Still’s disease, which, like Mtb, 
cause  a  chronic  inflammatory  state.  Through  these 
compari  sons, the authors [1] were able to cull the list of 
transcripts to a set of 86 that were indicative of active TB.
Transcriptional profiles reflect both the composition of 
the  sampled  cell  population  and  any  changes  in  RNA 
abundance within those cells. O’Garra and colleagues [1] 
found that differences in circulating cells and changes in 
gene expression both contributed to the transcriptional 
signature  that  identified  TB  patients.  For  example, 
patients  with  active  disease  had  a  reduction  in  T  cell 
transcripts  that  was  associated  with  fewer  circulating 
CD4+  and  CD8+  T  cells  rather  than  a  change  in  RNA 
abundance in these T cells, which was similar in patients 
and controls. On the other hand, whereas myeloid cell 
numbers  were  similar  among  the  patient  and  control 
groups, their transcript content differed markedly.
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patients with active disease and those with latent or no 
infection were due to transcripts that are characteristic of 
cells, particularly neutrophils, produced in response to 
both interferon (IFN)-γ and IFN-αβ. The identification of 
an  IFN-αβ  response  signature  in  a  systemic  bacterial 
infection  is  perhaps  surprising  for  those  who  consider 
these cytokines characteristic of responses to viral patho-
gens. However, bacteria such as Mtb that reside within 
host cells and deliver bacterial material into the host cell 
cytosol activate cytosolic innate immune receptors and 
trigger an IFN-αβ response [2]. Because group A Strepto­
coccus and S. aureus do not similarly activate cytosolic 
pattern receptors, further work will be required to deter-
mine  whether  the  86-gene  signature  that  O’Garra  and 
colleagues [1] identified will distinguish Mtb from these 
kinds of bacteria, which include common pathogens such 
as  Salmonella  typhi,  in  addition  to  relevant  viral 
infections such as HIV.
What do these transcriptional responses mean for the 
pathogenesis of disease? Although, like any observational 
study,  the  findings  are  only  correlative,  some  of  the 
factors  identified  [1]  are  well  known  to  be  important 
determinants of susceptibility to infection. In particular, 
individuals with abnormalities in IFN-γ signaling path-
ways are far more likely to develop progressive disease 
after  exposure  to  mycobacteria  [3].  However,  extrapo-
lating  to  other  genes  might  be  difficult.  In  fact,  by 
definition, patients with active TB are precisely those that 
failed to control initial infection. Thus, the transcriptional 
responses in these patients may mark a failure of immune 
control  or  reflect  inflammatory  responses  to  disease 
rather than TB-specific immune mechanisms.
Given  this  problem,  it  is  interesting  that  the  trans-
criptional  signature  [1]  does  not  distinguish  perfectly 
between active disease and latent infection. Between 10 
and 25% of the latently infected individuals had trans-
criptional profiles that clustered with those from patients 
with active disease. It is intriguing to speculate that the 
overlap between active and latent disease is more than 
simply a statistical fluke. The transcriptional signatures 
indicative  of  active  disease  were  more  pronounced  in 
individuals with greater radiographic evidence of disease, 
and  they  changed  following  treatment.  These  data 
suggest  that  the  transcriptional  signature  reflects 
bacterial  burden.  Thus,  it  is  possible  that  the  patients 
with  clinically  latent  disease  but  transcriptional  signa-
tures consistent with active disease have greater bacterial 
burdens than other latently infected patients.
In fact, recent evidence suggests that active and latent 
infections are not binary but, instead, represent different 
ends of a continuum of disease [4]. This new paradigm of 
TB  is  largely  based  on  studies  in  nonhuman  primates, 
including the cynomolgus macaque [5]. In these primates, 
active and latent disease seem to be overlapping entities 
rather  than  clearly  distinct  syndromes.  The  ability  to 
measure Mtb burden in humans could help us toward a 
more  relevant  model  of  the  diversity  of  disease  states. 
Importantly,  those  with  high  burdens  of  organisms,  as 
detected by transcriptional patterns, despite clinical latency 
might have the highest risk of progression to active TB.
Does the transcriptional signature identified by O’Garra 
and colleagues [1] provide a better way to diagnose active 
TB? Perhaps in the future; however, in many areas of the 
world where TB is now prevalent, even simple clinical 
ways to diagnose TB, such as microscopic observation of 
sputum  smears,  taxes  the  available  resources,  and 
measuring  hundreds  of  transcriptional  parameters,  or 
even a single transcript, is currently impossible. However, 
there are many findings from this study [1] that could be 
applied in research environments today. If transcriptional 
analysis  truly  can  be  used  to  measure  the  bacterial 
burden,  it  could  be  used  to  help  understand  the 
pathogenesis of disease and to predict those at highest 
risk  of  active  disease.  In  addition,  we  currently  have 
almost no way of measuring responses to treatment aside 
from assessing clinical parameters and relapse rates, both 
of which are slow and insensitive. A set of transcripts that 
correlates  highly  with  treatment  response  could 
revolutionize how drug testing is performed.
The host response might well be an imperfect reflection 
of the molecular events that occur during TB. It is easy to 
believe  that  different  individuals  might  vary  in  their 
response to a similar number of pathogens. In particular, 
those  with  HIV  are  likely  to  produce  a  very  different 
transcriptional  pattern  from  those  with  no  immune 
compromise, and it will be critical to test the predictions 
of  the  current  study  in  an  HIV-infected  population. 
Nevertheless, studies such as this one [1] represent a real 
opportunity to develop new insights into TB.
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